MedTrace Logo

Comparison Between Sevoflurane and Propofol for Maintenance of Sedation During ERCP

NCT05996588 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 86

Last updated 2023-08-18

No results posted yet for this study

Summary

After approval of ethical committee of Sindh Institute of Urology \& Transplantation (SIUT), 86 patients were enrolled for the elective endoscopic retrograde cholangiopancreatography (ERCP). Randomization was done by a computer-generated randomization table. Patients were divided in two groups based on agents used for the research study. Both the groups were induced by injection midazolam 0.06 mg/kg body weight and injection nalbuphine 0.1 mg/kg body weight. In group A, anesthesia was maintained by Sevoflurane inhalation via nasal prongs with oxygen to achieve minimum alveolar concentration (MAC) approximately 0.25%. Whereas, in Group B propofol infusion at 50 ug/Kg/min started for maintenance of anaesthesia. Ketamine 0.5mg/kg intravenously was used to rescue the sedation level in both groups

Conditions

  • Sedation Complication

Interventions

DRUG

Propofol 1 % Injectable Suspension

Propofol 1 % Injectable Suspension at a rate of 50 microgram/kg/min intravenously

DRUG

Sevoflurane

Sevoflurane inhalation anaesthetic at a concentration of 4-5% to achieve a MAC of 0.25

Sponsors & Collaborators

  • Sindh Institute of Urology and Transplantation

    lead OTHER

Principal Investigators

  • Muhammad Q Abbas, FCPS · Professor Dept of Anaesthesiology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-01-05
Primary Completion
2022-11-25
Completion
2022-11-25
FDA Drug
Yes

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05996588 on ClinicalTrials.gov